Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central anxious technique, conolidine modulates alternate molecular targets. A Science Advancements analyze identified that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://chelwoodh229bce1.targetblogs.com/profile